Paying users zone. Data is covered by .

  • Get to Eli Lilly & Co. for $15.99, or

  • get to whole website for at least 3 months from $49.99.

 

$15.99


Current Valuation Ratios

Eli Lilly & Co., current price multiples

 
Eli Lilly & Co. Abbott Laboratories AbbVie Inc. Allergan PLC Amgen Inc. Biogen Inc. Bristol-Myers Squibb Co. Celgene Corp. Gilead Sciences Inc. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Pharmaceuticals & Biotechnology Health Care
Selected Financial Data
Current share price (P) $
No. shares of common stock outstanding
 
Earnings per share (EPS) $
Operating profit per share $
Sales per share $
Book value per share (BVPS) $
Ratios (Price Multiples)
Price to operating profit (P/OP)
Price to sales (P/S)
Price to book value (P/BV)

If company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.

Otherwise, if company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.

Top


Historical Valuation Ratios (Summary)

Eli Lilly & Co., historical price multiples

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Price to earnings (P/E)
Price to operating profit (P/OP)
Price to sales (P/S)
Price to book value (P/BV)
Ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Eli Lilly & Co.'s P/E ratio declined from 2015 to 2016 and from 2016 to 2017.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Eli Lilly & Co.'s P/OP ratio declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Eli Lilly & Co.'s P/S ratio increased from 2015 to 2016 but then declined significantly from 2016 to 2017.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company's required rate of return and its actual rate of return. Eli Lilly & Co.'s P/BV ratio increased from 2015 to 2016 and from 2016 to 2017.

Top


Price to Earnings (P/E)

Eli Lilly & Co., historical P/E calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
No. shares of common stock outstanding1
Selected Financial Data (USD $)
Net income (loss) (in thousands)
Earnings per share (EPS)3
Share price1, 2
Ratio
P/E ratio4
Benchmarks
P/E Ratio, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
P/E Ratio, Sector
Pharmaceuticals & Biotechnology
P/E Ratio, Industry
Health Care

1 Data adjusted for splits and stock dividends.

2 Close price on the filing date of Eli Lilly & Co.'s Annual Report.

2017 Calculations

3 EPS = Net income (loss) ÷ No. shares of common stock outstanding
= ÷ =

4 P/E ratio = Share price ÷ EPS
= ÷ =

Ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Eli Lilly & Co.'s P/E ratio declined from 2015 to 2016 and from 2016 to 2017.

Top


Price to Operating Profit (P/OP)

Eli Lilly & Co., historical P/OP calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
No. shares of common stock outstanding1
Selected Financial Data (USD $)
Operating income (in thousands)
Operating profit per share3
Share price1, 2
Ratio
P/OP ratio4
Benchmarks
P/OP Ratio, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
P/OP Ratio, Sector
Pharmaceuticals & Biotechnology
P/OP Ratio, Industry
Health Care

1 Data adjusted for splits and stock dividends.

2 Close price on the filing date of Eli Lilly & Co.'s Annual Report.

2017 Calculations

3 Operating profit per share = Operating income ÷ No. shares of common stock outstanding
= ÷ =

4 P/OP ratio = Share price ÷ Operating profit per share
= ÷ =

Ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Eli Lilly & Co.'s P/OP ratio declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.

Top


Price to Sales (P/S)

Eli Lilly & Co., historical P/S calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
No. shares of common stock outstanding1
Selected Financial Data (USD $)
Revenue (in thousands)
Sales per share3
Share price1, 2
Ratio
P/S ratio4
Benchmarks
P/S Ratio, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
P/S Ratio, Sector
Pharmaceuticals & Biotechnology
P/S Ratio, Industry
Health Care

1 Data adjusted for splits and stock dividends.

2 Close price on the filing date of Eli Lilly & Co.'s Annual Report.

2017 Calculations

3 Sales per share = Revenue ÷ No. shares of common stock outstanding
= ÷ =

4 P/S ratio = Share price ÷ Sales per share
= ÷ =

Ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Eli Lilly & Co.'s P/S ratio increased from 2015 to 2016 but then declined significantly from 2016 to 2017.

Top


Price to Book Value (P/BV)

Eli Lilly & Co., historical P/BV calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
No. shares of common stock outstanding1
Selected Financial Data (USD $)
Total Eli Lilly and Company shareholders' equity (in thousands)
Book value per share (BVPS)3
Share price1, 2
Ratio
P/BV ratio4
Benchmarks
P/BV Ratio, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
P/BV Ratio, Sector
Pharmaceuticals & Biotechnology
P/BV Ratio, Industry
Health Care

1 Data adjusted for splits and stock dividends.

2 Close price on the filing date of Eli Lilly & Co.'s Annual Report.

2017 Calculations

3 BVPS = Total Eli Lilly and Company shareholders' equity ÷ No. shares of common stock outstanding
= ÷ =

4 P/BV ratio = Share price ÷ BVPS
= ÷ =

Ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company's required rate of return and its actual rate of return. Eli Lilly & Co.'s P/BV ratio increased from 2015 to 2016 and from 2016 to 2017.

Top